January 11, 2023
1 minute read
A team of three Ohio research companies has won an eight-year, $149 million, unlimited delivery, unlimited quantity contract instrument seat at the National Institute of Neurological Disorders and Stroke.
The team, comprising AmplifyBio and Andelyn Biosciences, will provide manufacturing and nonclinical support for the translational development of therapeutic biotechnology products in the NIH’s drug discovery and development program for neurological disorders, according to a Battelle release. provide.
A partnership of three Ohio-based companies has been awarded contract seats to support the translational development of therapeutic biotechnology products in NIH’s drug discovery and development programs to address neurological disorders. Source: Adobe Stock
“This agreement will be used to advance innovative therapies, including cell and gene therapies, for a variety of neurological diseases.” Drew Cawson, Battelle’s business line director of life science research said in a release. “We are investigating new and novel ways to treat rare diseases for which there are no effective treatments yet.”
Battelle will provide assay support and integration services to support regulatory approvals, as well as a history of federal contracting experience to support its prime contractor status, the company said in a release. I’m here.
“The success of this proposed tender allows AmplifyBio to demonstrate our continued partnership with Battelle and to formally enter into a new partnership with Andelyn Biosciences.” jerry hacker AmplifyBio Executive Vice President and Chief Commercial Officer said: “We look forward to bringing our expertise in advanced therapeutic analytics and preclinical research capabilities to accelerate breakthrough treatments for neurological diseases.”
The companies will work together on the winning proposal, and according to the release, each partner will receive an equal share of the work stipulated in the contract, relying on each organization’s differentiated strengths to meet client needs. I am looking forward to
“We are proud to support this research program.” Eric Blair Andelyn’s chief commercial officer said in a release: “We are committed to making an impact when it comes to manufacturing therapeutics, especially when it comes to treating rare diseases.”
